Guest: Ravindra Ganesh, M.B.B.S., M.D. and Raymund R. Razonable, M.D. 

Host: Amit K. Ghosh, M.D. (@AmitGhosh006) 

In this episode, Ravindra Ganesh, M.B.B.S., M.D. and Raymund R. Razonable, M.D. join Amit K. Ghosh, M.D. to review the use of monoclonal antibody as a new antiviral agent in the treatment of COVID-19 infection. 

Who is most likely to benefit from monoclonal antibody infusions? Drs. Ganesh and Razonable, discuss recent studies on monoclonal antibody infusions in patients with mild to moderate COVID-19 infections. Also discussed are the logistical challenges faced and the innovative solutions that were implemented while administering this therapy, particularly navigating the acceptance of treatment, its real and perceived side effects, and lack of awareness due to inequity and poverty. Research on the development of subcutaneous or intramuscular administration for prophylaxis against COVID-19 in patients at high risk for complications or at high risk for being exposed to SARS-CoV-2 is also discussed in this episode. 

Additional resources: 

• AskMayoExpert COVID-19 Navigator: https://askmayoexpert.mayoclinic.org/navigator/COVID-19 

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.